

**GOVERNMENT OF INDIA  
MINISTRY OF CHEMICALS & FERTILIZERS  
DEPARTMENT OF PHARMACEUTICALS**

LOK SABHA  
UNSTARRED QUESTION NO. 1026  
TO BE ANSWERED ON 3<sup>rd</sup> December, 2021

**Drugs under Price Control**

**1026. SHRI VELUSAMY p.:**

Will the Minister of **CHEMICALS AND FERTILIZERS** be pleased to state:

- (a) the total number of drugs that have been placed under price control by National Pharmaceutical Pricing Authority (NPPA) as on date;
- (b) whether the Ministry has received any objection from the multinational pharma companies as well as Indian pharma giants;
- (c) if so, the details thereof;
- (d) whether the NPPA has issued any order that will cover the National List of Essential Medicines (NLEM) and also non essential drugs; and
- (e) if so, the details thereof and if not, the reasons therefor?

**ANSWER**

**MINISTER IN THE MINISTRY OF CHEMICALS & FERTILIZERS  
(DR. MANSUKH MANDAVIYA)**

---

(a): The details of drugs, including medical devices, placed under price control by the National Pharmaceutical Pricing Authority (NPPA) under the Department of Pharmaceuticals (DoP) are as under:

- (i) Ceiling prices of 882 scheduled formulations fixed under Schedule-I of Drugs Price Control Order, 2013 (DPCO, 2013) including the ceiling prices of four scheduled medical devices, i.e., Hormone releasing IUD, IUD containing Copper, Bare metal stents and Drug Eluting Stents;
- (ii) Fixed Retail price of 1,703 new drugs under the DPCO, 2013;
- (iii) Fixed Ceiling price of Orthopaedic Knee Implants under Para 19 of the DPCO, 2013 in public interest;

Further, NPPA capped Trade Margin of non-scheduled formulations of 42 Anti-cancer medicines under “Trade Margin Rationalization” approach as a Pilot for proof of concept and regulated the prices of Oxygen Concentrators, Pulse Oximeter, Blood Pressure Monitoring Machine, Nebulizer, Digital Thermometer and Glucometer under “Trade Margin Rationalization” Approach invoking Para 19 of the DPCO, 2013.

(b) & (c): The representations from the industry and Pharma Associations on various issues are received from time to time, which are addressed suitably.

(d) & (e): NPPA regulates the price of drugs as per provisions of DPCO, 2013 based upon the National Pharmaceutical Pricing Policy, 2012 (NPPP, 2012), which follows the principles of essentiality and market-based pricing. DPCO, 2013 mandates the fixation of ceiling price based on average price in the market in respect of scheduled formulations listed in the National List of Essential Medicines (NLEM) and allows an annual price rise based on Wholesale Price Index (WPI). DPCO, 2013 further mandates monitoring of retail price fixed by manufacturers in respect of non-scheduled formulations allowing an annual price increase of up to 10%. Instances of overcharging are dealt with by NPPA under the relevant provisions of DPCO 2013.

\*\*\*\*\*